On Friday, Shares of Nike Inc (NYSE:NKE), subtract -0.48% and closed at $51.79 in the last trading session. The last trading range of the stock ranges between $51.68 and $52.46. The company’s Market capitalization is $86.50 Billion with the total Outstanding Shares of 1.33 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $51.47 and reached to max level of $68.19. NIKE, Inc. (NKE) declared recently that Tom Peddie becomes the new VP, GM of North America, succeeding Joaquin Hidalgo, who has served in this role since July 2013 and will be taking a leave of absence to focus on his health. This change is effective right away.
Peddie, a 26-year Nike veteran, has held senior administration roles across Nike, counting VP North America Sales and VP Global Sales. He was formerly VP, GM of Emerging Markets and joined the North America team earlier this year as VP, GM of Integrated Marketplace, where he has led Nike’s holistic integrated market strategy in North America.
“Tom is a strong leader with a deep understanding of our consumer and the integrated marketplace,” said Elliott Hill, President of Geographies and Sales, Nike Brand. “He has proven time and again his ability to lead teams toward continued and profitable long-term growth and we look forward to his leadership in this important geography.”
CIT Group Inc. (NYSE:CIT), jumped 1.46% and closed at $36.93 in the last trading session. The last trading range of the stock ranges between $36.17 and $37.98. The company’s Market capitalization is $7.57 Billion with the total Outstanding Shares of 201.99 million. During the 52-week trading session the minimum price at which share price traded, registered at $25.18 and reached to max level of $46.51. CIT Group Inc. (CIT), a leading provider of commercial lending and leasing services, declared recently that it has reached a definitive agreement to sell CIT Commercial Air, its commercial aircraft leasing business, to Avolon Holdings Limited (“Avolon”), the international aircraft leasing company and a wholly-owned partner of Bohai Capital Holding Co. Ltd. The transaction is expected to close by the end of the first quarter of 2017, subject to regulatory approvals and customary closing conditions.
CIT has received a “non-objection” from the Federal Reserve Bank of New York for its Amended Capital Plan subject to the closing of the transaction. The Amended Capital Plan authorizes CIT to return $2.975 billion of common equity to shareholders from the net proceeds of the sale; return up to an additional $0.325 billion of common equity contingent upon the issuance of a similar amount of Tier 1 qualifying preferred stock; and pay common dividends totaling $64 million per year after the transaction is accomplished, subject to quarterly approval by the CIT Board of Directors.
On the other hand share Opko Health Inc. (NASDAQ:OPK), lost -4.99% and closed at $9.91 in the last trading session. The last trading range of the stock ranges between $9.53 and $9.93. The company’s Market capitalization is $5.18 Billion with the total Outstanding Shares of 550.38 million. During the 52-week trading session the minimum price at which share price traded, registered at $7.12 and reached to max level of $11.85. OPKO Health, Inc. (OPK), declares the appointment of Benjamin D. Solomon, M.D. as Managing Director of GeneDx, effective as of October 3, 2016. GeneDx, part of OPKO’s BioReference Laboratories partner, specializes in genetic testing for rare hereditary disorders.
Dr. Solomon is a pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients with both rare and common genetic conditions. He is a leader in integrating cutting-edge technologies to better manage health and disease. He most recently served as Chief of the Division of Medical Genomics at the Inova Translational Medicine Institute, a clinical research institute dedicated to putting genomic medicine into action.
“We are very proud to have Dr. Solomon join the OPKO Health team as the new leader of our GeneDx division, a world-class genomics laboratory. A recognized leader in his field, Dr. Solomon’s expertise in genomics and genetics will be of great value as we continue to leverage leading technologies to build and expand GeneDx’s global role in diagnostic and laboratory services. His passion for finding answers for patients and clinicians and his talent and experience in the integration of genomics into the practice of medicine will enhance the numerous and diverse communities in the U.S. and worldwide that benefit from the outstanding diagnostic services our laboratories offer,” said Gregory S. Henderson, M.D., Ph.D., President of BioReference Laboratories.